Current Drug Therapy

The role of SGLT-2 inhibitors in managing type 2 diabetes

Yumiko Tsushima, MD, M. Cecilia Lansang, MD, MPH and Vinni Makin, MBBS, MD, FACE
Cleveland Clinic Journal of Medicine January 2021, 88 (1) 47-58; DOI: https://doi.org/10.3949/ccjm.88a.20088

Article Information

vol. 88 no. 1 47-58
DOI 
https://doi.org/10.3949/ccjm.88a.20088
PubMed 
33384315
Published By 
Cleveland Clinic Journal of Medicine
Print ISSN 
0891-1150
Online ISSN 
1939-2869
History 
  • Published online December 31, 2020.
Copyright & Usage 
Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

Author Information

  1. Yumiko Tsushima, MD
  1. Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic
  1. M. Cecilia Lansang, MD, MPH
  1. Director, Main Campus Department of Endocrinology, Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic; Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  1. Vinni Makin, MBBS, MD, FACE⇑
  1. Director, East Region, Department of Endocrinology Diabetes, and Metabolism, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  1. Address:
    Vinni Makin, MBBS, MD, FACE, Department of Endocrinology Diabetes, and Metabolism, F20, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; makinv{at}ccf.org
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects